Zimmer Biomet reports Q3 2026 results and lifts full‑year guidance
Zimmer Biomet Holdings reported third‑quarter 2026 net sales of $2.063 billion, up 3.1% year‑over‑year on a reported basis and 3.7% in constant currency. Diluted earnings per share were $1.00, a 13.8% decline, while adjusted EPS was $1.90, flat versus the prior year. The company raised its full‑year 2026 organic constant‑currency revenue growth outlook to 3.0%‑3.5% and adjusted EPS guidance to $8.50‑$8.60. CEO Ivan Tornos highlighted strong performance in hips, S.E.T. and technology franchises and the extension of a distribution agreement with THINK Surgical.
Why it matters
The higher revenue and EPS guidance expands the upside for investors, as the new targets exceed prior expectations (the company lifted guidance, per the press release). The raised outlook also suggests stronger cash‑flow generation, with operating cash flow of $560 million and free cash flow of $372.4 million in the quarter.
Key facts
- 1Third‑quarter net sales were $2.063 billion, up 3.1% on a reported basis and 3.7% in constant currency. prnewswire.com
- 2Diluted earnings per share were $1.00, a decrease of 13.8%; adjusted diluted EPS was $1.90, consistent with the prior year period. prnewswire.com
- 3Operating cash flow was $560.0 million and free cash flow was $372.4 million in the quarter. prnewswire.com
- 4Full‑year 2026 organic constant‑currency revenue growth guidance was updated to 3.0%‑3.5% (previously 2.25%‑3.25%). prnewswire.com
- 5Adjusted diluted EPS guidance for 2026 was raised to $8.50‑$8.60 (previously $8.47‑$8.59). prnewswire.com
- 6CEO Ivan Tornos said the hips, S.E.T. and technology franchises grew at upper‑single‑digit or double‑digit rates, supporting the guidance lift. prnewswire.com
Summary written by AlphAI AI Desk from 14 of 14 sources. Not investment advice. Figures are as stated by the linked sources.